Small-Cell Lung Cancer - Pipeline Review, H1 2016


#739341

645pages

Global Markets Direct

$ 2000

In Stock

Small-Cell Lung Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Small-Cell Lung Cancer - Pipeline Review, H1 2016, provides an overview of the Small-Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
- The report reviews pipeline therapeutics for Small-Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Small-Cell Lung Cancer therapeutics and enlists all their major and minor projects
- The report assesses Small-Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 7
Small-Cell Lung Cancer Overview 8
Therapeutics Development 9
Small-Cell Lung Cancer - Therapeutics under Development by Companies 11
Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 16
Small-Cell Lung Cancer - Pipeline Products Glance 17
Small-Cell Lung Cancer - Products under Development by Companies 20
Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes 27
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development 28
Small-Cell Lung Cancer - Therapeutics Assessment 100
Drug Profiles 122
Small-Cell Lung Cancer - Recent Pipeline Updates 372
Small-Cell Lung Cancer - Dormant Projects 614
Small-Cell Lung Cancer - Discontinued Products 621
Small-Cell Lung Cancer - Product Development Milestones 623
Appendix 631

List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H1 2016 22
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2016 23
Number of Products under Development by Companies, H1 2016 24
Number of Products under Development by Companies, H1 2016 (Contd..1) 25
Number of Products under Development by Companies, H1 2016 (Contd..2) 26
Number of Products under Development by Companies, H1 2016 (Contd..3) 27
Number of Products under Development by Companies, H1 2016 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Comparative Analysis by Late Stage Development, H1 2016 30
Comparative Analysis by Clinical Stage Development, H1 2016 31
Comparative Analysis by Early Stage Development, H1 2016 32
Products under Development by Companies, H1 2016 33
Products under Development by Companies, H1 2016 (Contd..1) 34
Products under Development by Companies, H1 2016 (Contd..2) 35
Products under Development by Companies, H1 2016 (Contd..3) 36
Products under Development by Companies, H1 2016 (Contd..4) 37
Products under Development by Companies, H1 2016 (Contd..5) 38
Products under Development by Companies, H1 2016 (Contd..6) 39
Products under Investigation by Universities/Institutes, H1 2016 40
Small-Cell Lung Cancer - Pipeline by 4SC AG, H1 2016 41
Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 42
Small-Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2016 43
Small-Cell Lung Cancer - Pipeline by Alchemia Limited, H1 2016 44
Small-Cell Lung Cancer - Pipeline by Amgen Inc., H1 2016 45
Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H1 2016 46
Small-Cell Lung Cancer - Pipeline by Aposense Ltd., H1 2016 47
Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H1 2016 48
Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2016 49
Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 50
Small-Cell Lung Cancer - Pipeline by Bayer AG, H1 2016 51
Small-Cell Lung Cancer - Pipeline by BeiGene, Ltd., H1 2016 52
Small-Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H1 2016 53
Small-Cell Lung Cancer - Pipeline by BioLineRx, Ltd., H1 2016 54
Small-Cell Lung Cancer - Pipeline by Bionomics Limited, H1 2016 55
Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 56
Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 57
Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2016 58
Small-Cell Lung Cancer - Pipeline by Cellceutix Corporation, H1 2016 59
Small-Cell Lung Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 60
Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 61
Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 62
Small-Cell Lung Cancer - Pipeline by CytRx Corporation, H1 2016 63
Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016 64
Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2016 65
Small-Cell Lung Cancer - Pipeline by Exelixis, Inc., H1 2016 66
Small-Cell Lung Cancer - Pipeline by G1 Therapeutics, Inc., H1 2016 67
Small-Cell Lung Cancer - Pipeline by Genzyme Corporation, H1 2016 68
Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 69
Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H1 2016 70
Small-Cell Lung Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016 71
Small-Cell Lung Cancer - Pipeline by Immunomedics, Inc., H1 2016 72
Small-Cell Lung Cancer - Pipeline by Incyte Corporation, H1 2016 73
Small-Cell Lung Cancer - Pipeline by Ipsen S.A., H1 2016 74
Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2016 75
Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 76
Small-Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 77
Small-Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 78
Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H1 2016 79
Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 80
Small-Cell Lung Cancer - Pipeline by MedImmune, LLC, H1 2016 81
Small-Cell Lung Cancer - Pipeline by Medivation, Inc., H1 2016 82
Small-Cell Lung Cancer - Pipeline by MEI Pharma, Inc., H1 2016 83
Small-Cell Lung Cancer - Pipeline by Merck & Co., Inc., H1 2016 84
Small-Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 85
Small-Cell Lung Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2016 86
Small-Cell Lung Cancer - Pipeline by MolMed S.p.A., H1 2016 87
Small-Cell Lung Cancer - Pipeline by Mologen AG, H1 2016 88
Small-Cell Lung Cancer - Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016 89
Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2016 90
Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016 91
Small-Cell Lung Cancer - Pipeline by Novartis AG, H1 2016 92
Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016 93
Small-Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 94
Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 95
Small-Cell Lung Cancer - Pipeline by Onxeo SA, H1 2016 96
Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2016 97
Small-Cell Lung Cancer - Pipeline by Pfizer Inc., H1 2016 98
Small-Cell Lung Cancer - Pipeline by Pharma Mar, S.A., H1 2016 99
Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 100
Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 101
Small-Cell Lung Cancer - Pipeline by SciTech Development, LLC , H1 2016 102
Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 103
Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 104
Small-Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 105
Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals, Inc., H1 2016 106
Small-Cell Lung Cancer - Pipeline by Tarveda Therapeutics, Inc., H1 2016 107
Small-Cell Lung Cancer - Pipeline by Tesaro, Inc., H1 2016 108
Small-Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 109
Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 110
Small-Cell Lung Cancer - Pipeline by ViiV Healthcare Limited, H1 2016 111
Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016 112
Assessment by Monotherapy Products, H1 2016 113
Assessment by Combination Products, H1 2016 114
Number of Products by Stage and Target, H1 2016 116
Number of Products by Stage and Mechanism of Action, H1 2016 125
Number of Products by Stage and Route of Administration, H1 2016 132
Number of Products by Stage and Molecule Type, H1 2016 134
Small-Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2016 385
Small-Cell Lung Cancer - Dormant Projects, H1 2016 627
Small-Cell Lung Cancer - Dormant Projects (Contd..1), H1 2016 628
Small-Cell Lung Cancer - Dormant Projects (Contd..2), H1 2016 629
Small-Cell Lung Cancer - Dormant Projects (Contd..3), H1 2016 630
Small-Cell Lung Cancer - Dormant Projects (Contd..4), H1 2016 631
Small-Cell Lung Cancer - Dormant Projects (Contd..5), H1 2016 632
Small-Cell Lung Cancer - Dormant Projects (Contd..6), H1 2016 633
Small-Cell Lung Cancer - Discontinued Products, H1 2016 634
Small-Cell Lung Cancer - Discontinued Products (Contd..1), H1 2016 635


List of Figures
Number of Products under Development for Small-Cell Lung Cancer, H1 2016 22
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2016 23
Number of Products under Development by Companies, H1 2016 24
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Comparative Analysis by Late Stage Development, H1 2016 30
Comparative Analysis by Clinical Stage Development, H1 2016 31
Comparative Analysis by Early Stage Products, H1 2016 32
Assessment by Monotherapy Products, H1 2016 113
Assessment by Combination Products, H1 2016 114
Number of Products by Top 10 Targets, H1 2016 115
Number of Products by Stage and Top 10 Targets, H1 2016 115
Number of Products by Top 10 Mechanism of Actions, H1 2016 124
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 124
Number of Products by Routes of Administration, H1 2016 131
Number of Products by Stage and Routes of Administration, H1 2016 131
Number of Products by Top 10 Molecule Types, H1 2016 133
Number of Products by Stage and Top 10 Molecule Types, H1 2016 133